| Drug Type Bispecific T-cell Engager (BiTE) | 
| Synonyms- | 
| Target | 
| Action inhibitors, stimulants | 
| Mechanism CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), CD3 stimulants(T cell surface glycoprotein CD3 stimulants) | 
| Therapeutic Areas | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Chronic Lymphocytic Leukemia | Preclinical | Germany  | 03 Aug 2024 | |
| Diffuse Large B-Cell Lymphoma | Preclinical | Germany  | 03 Aug 2024 | |
| Small Lymphocytic Lymphoma | Preclinical | Germany  | 03 Aug 2024 | 






